Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are functional diseases without identified organic cause and intruduced as part of the Rome III criteria published in 2006. Because of non-organic diseases, pharmacological treatment (not invasive surgical treatment) is the preferred therapy for such diseases. Meanwhile, evidence-based clinical practice guidelines for FD and IBS have been published in Japan. However, no definite therapeutic strategy for FD and IBS has yet been established. To understand more appropriate treatments according to the respective pathophysiology, this review introduces the several pharmacological treatments including current standards and proposes future promising therapies based on these guidelines. First, this review covered clinical evidence for standard and recommended drugs such as acid suppressants, prokinetics, probiotics, and bulking polymers for the management of FD and IBS. Next, this review progressed to propose future promising treatments for their managements. A comprehensive understanding of relevant therapeutic regimens and pharmacological treatment using drug candidates including future promising drugs is required for the optimal and more effective treatment of FD and IBS.
Introduction
The disease classification of functional gastrointestinal disorders (FGIDs), which was intruduced as part of the diseases of FGIDs in clinics and hospitals. The pathophysiologies of FD and IBS involve multiple factors including psychosomatic factors associated with the central nervous system (CNS) and physiological disorders of the gastrointestinal tracts.
1 Therefore, it may be difficult to comprehensively recognize the pathophysiology of FD and IBS. Accumulating evidence based on basic and clinical research has demonstrated detailed mechanisms of the pathophysiology of these diseases. As a result, some effective pharmacological treatment regimens have been proved and can improve symptoms in patinets with FD and IBS. Meanwhile, evidence-based clinical practice guidelines for FD and IBS have been published in Japan. 2, 3 In these guidelines, the use of standard drugs according to the respective pathophysiology is recommended to treat these diseases. Although the drugs recommended in the above guidelines primarily target the gastrointestinal tract, such therapies do not always relieve such characteristic abdominal symptoms.
Therefore, it is thought that a comprehensive understanding of relevant therapeutic regimens and drug candidates is required for the optimal treatment of FD and IBS. This review summarizes the efficacies of the present pharmacological treatments for FD and IBS, and proposes promising therapeutic options incorporating other drugs.
Pharmacological Treatment for FD at Present
In general, a treatment strategy for FD must be established in accordance with the pathophysiology of this disease as well as other related diseases. The pathophysiology of FD involves personality disorders, 4 anxiety and depression, 5 acid secretion, 6 the autonomic nervous system, 7 gastrointestinal motility, 8 and Helicobacter pylori infection, 9 and so on ( Figure 1 ).
Although various related factors are gradually going to be elucidated, no definite and conclusive treatment regimen has yet been established, presumably reflecting the complicated interaction of multiple factors of FD. 10 In our institute, diagnostic and treatment flow ( Figure 2 ) is recommended mainly according to the presence/absence of motility disorders (each prevalence rate of motility disorders in Figure 2 was derived from our previous report 8 ), because motility disorders of gastric accommodation and emptying are important for the pathophysiology of FD among multiple factors.
Initially, differential diagnosis must be performed by questionnaires, diagnostic criteria, and examinations for several organic diseases for patients with dyspeptic symptoms. After the diagnosis of FD, we evaluated the Pharmacological Treatment for FGIDs severity of abdominal and psychological symptoms by the questionnaires such as the Gastrointestinal Symptom Rating Scale, the Zung Self-rating Depression Scale, and the State-Trait Anxiety Inventory, and the gastric motility as a functional test of the stomach. If gastric motility of patients with FD can be assessed in every institute, we believe this flow must be useful for its treatment and management. Because most institutes cannot easily assess gastric motility, many physicians must generally rely on dyspeptic symptoms when they treat patients with FD. Unfortunately, however, dyspeptic symptoms (e.g. abdominal pain and abdominal discomfort) alone do not necessarily indicate the presence of closely associated pathophysiology such as gastroduodenal motility disorders and excessive acid secretion.
11 At present, treatment efficacy of FD using various drugs is generally reported as 50-60% in Japan. This section summarizes previous clinical reports that addressed efficacy of various treatments for FD.
1) H. pylori eradication therapy
There are many arguments regarding the association of H. pylori infection with the pathophysiology of FD, as diagnosed according to the Rome III criteria.
12,13
Meanwhile, a systematic review of H. pylori eradication therapy for FD revealed a 10% relative risk reduction of symptoms in the treated group compared to the placebo group. 14 The number needed to treat (NNT) was indicated to be 13 in this systematic review. Therefore, H. pylori infection may be associated with the pathogenesis, at least in a subset of patients with FD. Notably, the Japanese national health insurance program covers the cost of eradication therapy in patients with H. pylori-associated gastritis. However, in the course of daily management, many physicians find that dyspeptic symptoms such as abdominal pain and discomfort are not improved by H. pylori eradication therapy alone. Nevertheless, the Japanese clinical guideline for FD notes the potential relation- 2) Acid suppression therapy Acid suppressants such as proton pump inhibitors (PPIs) and histamine type 2 receptor antagonists (H 2 RA) often are used to treat various gastrointestinal diseases, including gastroduodenal ulcers and gastroesophageal reflux diseases. There also have been many clinical trials evaluating the efficacy of these acid suppressants for FD because it is reported that visceral hypersensitivity caused by gastric acid is closely associated with the pathogenesis of FD. 16 In patients with FD, these trials indicated response rates for esomeprazole and lansoprazole that were 10-15% over placebo. 17, 18 Furthermore, a double dose of rabeprazole was effective (63.5%) for treatment of FD especially in patients with abnormal acid reflux into the esophagus. 19 In Japan, an open label trial showed that the response rate of omeprazole was 67%, which was higher than that of other treatment groups (famotidine, mosapride, and teprenone). 20 In addition, randomized controlled trials (RCTs) using rabeprazole (the SAMURAI study)
showed that the complete and satisfactory relief rates of 20 mg rabeprazole were 11.4% and 17.1% over placebo in patients with investigated FD who met the Rome III criteria. 21 Accumulating lines of evidence, including the above data, indicated that the respective response rates for H 2 RA and PPIs were 22% and 14% over placebo in patients with non-ulcer dyspepsia in the Cochrane database systematic review. 22 On the basis of these findings, the Japanese clinical guideline for FD proposed a statement that acid suppressants are effective for the treatment of patients with FD.
2 However, the NNT of PPI in the treatment of FD was approximately 9 in this systematic review. Furthermore, PPIs and H 2 RAs provided the same level of efficacy and were effective for the treatment of FD, although there was a clear difference in acid suppression levels between the two drugs. Accordingly, it must be concluded that some problems remain to be elucidated for definitive establishment of acid suppressor therapy for FD, although acid suppressor therapy is recommended as a first-line therapy for FD.
3) Prokinetic therapy
Various clinical studies suggest that gastrointestinal motility disorders are strongly associated with dyspeptic symptoms in the pathogenesis of FD. 8, 23 Therefore, prokinetics is suggested to be effective for FD treatment. Indeed, in patients with FD, the response rate for itopride reported to exceed that of placebo by 22%. 24 However, subsequent report was not able to confirm the superiority of itopride. 25 In a Japanese megaclinical trial, mosapride was effective in relieving abdominal bloating and pain in patients with FD. 26 Together with these findings, it may be easy to understand that some meta-analyses indicated the efficacy of prokinetics for FD. 27 
Pharmacological Treatments of IBS at Present
As for FD, a treatment strategy of IBS also must be established in accordance with respective pathophysiology. Since most pathophysiological factors of IBS are similar to those of FD, the pharmacological treatment regimen for IBS is similar to that of FD. However, as for FD, no definitive and conclusive treatment regimen has yet been established for IBS. Among various factors, systemic stress-associated brain-gut interaction has been suggested as a possible mechanism of lower abdominal pain and discomfort derived from the colon.
In other words, the pathogenesis of IBS involves both the CNS and colon because some changes in CNS function alter perception and post-infectious mucosal inflammation is associated with abdominal symptoms of IBS. 40, 41 Therefore, ongoing research is investigating the brain-gut interaction to elucidate the pathophysiology of IBS and establish potential therapies.
Corticotropin-releasing factor, a stress-associated mediator, is secreted under stress conditions, yielding upregulation of colonic motility and causing visceral hypersensitivity. In addition, 5-HT, a neurotransmitter, has been associated with the pathogenesis of IBS. 
1) Bulking polymers therapy
Polycarbophil calcium is a polyacrylic resin that is hydrophilic but insoluble in water.
The compound maintains watery content in the gastrointestinal tract by acting like a soluble fiber, thereby regulating the transport of gastrointestinal content. The agent has been shown to ameliorate watery diarrhea and constipation in patients with IBS. 42 Furthermore, the resin attenuates the decreased threshold for painful stimulation and the reduced compliance of the rectum. Thus, this agent is recommended to be one of first selective drugs for use in IBS treatment. The efficacy of polycarbophil calcium has been proven in placebo-controlled RCTs as well as in large-scale clinical trials conducted in Japan. 43 2) Probiotic and prebiotic therapies Accumulating lines of evidence based on basic and clinical research on probiotics and prebiotics have shown the efficacy of these modalities for treatment of IBS. 44, 45 As a result, probiotics and prebiotics are (respectively) strongly and weakly recommended for treatment of patients with IBS. 3 However, there were somewhat inconsistent results among various reports depending on the respective bacterial species tested.
Thus, further clinical trials will be needed before definite recommendations can be made, especially for a Japanese population.
3) Prokinetic therapy
Trimebutine maleate inhibits (via ®-and ¬-opioid receptors) the release of acetylcholine from neurons in the myenteric plexus and has been proposed for use in the treatment of IBS. A systematic review indicated Pharmacological Treatment for FGIDs that the agent improved gastrointestinal symptoms, including abdominal pain, along with defecation frequency and stool consistency. 46 Therefore, the agent may be especially effective in patients with diarrheadominant IBS. In Western countries, the 5-HT 3 receptor antagonist alosetron significantly improved abdominal pain and discomfort, defecation urgency, defecation frequency and loose stool/diarrhea in female (but not male) diarrhea-dominant IBS patients. 47 In Japan, the 5-HT 3 receptor antagonist ramosetron showed significant efficacy in male (but not female) diarrhea-dominant IBS patients. 48 However, recently, the efficacy of ramosetron has been proved in female patients with diarrhea-dominant IBS.
Although the differences in efficacy of the respective 5-HT 3 receptor antagonist were due to a small number of patients recruited in the corresponding studies, 5- 
4) Other pharmacological therapies
A variety of candidates for IBS treatment are described in the evidence-based clinical practice guidelines for IBS, including anticholinergics, anti-diarrheal agents, laxatives, enemas, antidepressants, anxiolytics, antipsychotics or mood stabilizers, and kampo medicines. Although these drugs may be effective for some patients with IBS, a weak recommendation for the relevant applications are weak, because there are few clinical data regarding treatment efficacy for IBS.
5) Lifestyle management, dietary treatment, and cognitive behavior therapy
As well as treatment for FD, management of lifestyle and dietary habits is usually performed for patients with IBS. A recent RCT showed that a low fermentable oligo-di-monosaccharide and polyol diet, eliminating high fat foods and avoiding spicy foods, is effective for patients with IBS. 49 In addition, a meta-analysis, a fiber-rich diet was effective for constipation, but not for abdominal pain in IBS patients. 50 Other behavioral modifications, such as eliminating alcohol and smoking, getting good sleep, and taking rest, also might reduce IBS symptoms. Accordingly, a Japanese guideline for IBS suggests weak recommendation of management of lifestyle and dietary habits and behavioral modification. This guideline suggested that cognitive behavioral therapy also improves overall IBS symptoms and QOL three months after treatment than regular therapy or waiting for treatment initiation. However, to conclude definitely, further clinical study with larger samples will be needed. 
Pharmacological Treatments of IBS in the Future

